Health Tech Capitol | Exact Sciences’ stock soars on news that Pfizer will market Cologuard test
16340
post-template-default,single,single-post,postid-16340,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Exact Sciences’ stock soars on news that Pfizer will market Cologuard test

23 Aug Exact Sciences’ stock soars on news that Pfizer will market Cologuard test

Posted at 15:15h in Uncategorized by
0 Likes

Exact Sciences Corp. stock leaped more than 30 percent Wednesday after the Madison company announced that drug giant Pfizer will help sell Exact’s Cologuard non-invasive DNA stool test for colorectal cancer.

Pfizer will invest $20 million to $24 million a year, for a total of more than $65 million, between October 2018 and December 2021 to promote Cologuard. Exact will match those figures, on top of the annual $80 million it already pours into marketing.

Pfizer also promises to make at least 625,000 sales calls a year for Cologuard during that time period.

Exact CEO Kevin Conroy said the collaboration could be “a turning point” in the fight against colorectal cancer.

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.